Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients with Asthma.

Background: The consistency of fixed airflow limitation status during treatment in patients with asthma is unknown.

Objective: The objective of this study was to determine the consistency of fixed airflow obstruction (FAO) status during treatment and effects on treatment response.

Methods: This post hoc analysis from a 12-week study (NCT00652002) assessed patients aged 12 years or more with moderate-to-severe asthma randomized to twice-daily budesonide/formoterol (BUD/FM) via pressurized metered-dose inhaler (pMDI) 320/9 μg, BUD pMDI 320 μg, FM 9 μg via dry-powder inhaler, or placebo.

Biochemical and cellular mechanisms of aging and degenerative disease: excessive, poor-quality caloric intake may deplete essential nutrients and interfere with cellular processes to produce degenerative damage.

It has long been known that caloric restriction retards aging and many degenerative disease processes. Various experiments have confirmed that caloric restriction enables animals' organelles and cells to retain their structural integrity into old age, in contrast to ad libitum counterparts. Calorically restricted animals also maintain greatly enhanced immune and DNA repair systems, handle outside threats-infectious agents, toxins, radiation, extreme temperatures-more proficiently, and usually avoid or defer the onset of cancers.